I've theorized several times in the past that BOCX would be bought out once RECAF is seen as a viable technology, but the GE deal has me reconsidering that position somewhat.
I don't think GE will want to get into the pharmaceutical business because of product liability issues, but they might want to acquire the RECAF diagnostic and imaging portion of BOCX. That would fit nicely.
That would also provide BOCX with some capital for therapeutic research. I imagine that effort is going to require some serious money. Unless RECAF hits the market sometime soon and starts generating revenue (and brings up the stock price), I don't see how BOCX is going to fund therapeutics (other than just basic research) without getting in bed with big pharma.